Key Takeaways:
Shares of Zoetis Inc. (ZTS) plunged more than 20 percent Thursday after the animal-health company reported first-quarter results that missed analyst expectations and cut its full-year guidance.
"The first quarter unfolded in a more challenging operating environment than we anticipated. Pet owners demonstrated increased price sensitivity, resulting in a decline in veterinary visits and softer demand for premium innovative products,” CEO Kristin Peck said in the earnings release.
For the first quarter, Zoetis reported revenue of $2.26 billion, missing the consensus estimate of $2.3 billion. Earnings per share came in at $1.53, below Wall Street’s expectation for $1.60.
The stock fell to $88.94, putting it on pace for its lowest close in more than seven years and making it the session’s worst performer in the S&P 500. As a result of the challenging quarter, Zoetis lowered its 2026 profit guidance to between $6.85 and $7.00 a share and cut its revenue forecast to a range of $9.68 billion to $9.96 billion.
Analysts at Stifel, led by Jonathan Block, wrote that the quarter was “worse than it seems,” pointing to a $100 million operational revenue realignment that benefited the first quarter. Factoring this out, the analysts noted organic operational revenue growth was well below the consensus view, with significant weakness in the company's pet business segment.
The guidance reduction signals a potential contraction in consumer spending on pet care, a sector that had previously shown resilience to economic pressures. The sharp sell-off could trigger further analyst downgrades and a broader re-evaluation of valuations for companies reliant on discretionary pet spending.
The stock is now down 29 percent year-to-date. The significant earnings miss and guidance cut suggest management expects weaker consumer demand to persist. Investors will be closely watching the company's next earnings report for signs of stabilization in vet visits and product demand.
This article is for informational purposes only and does not constitute investment advice.
